Details
Stereochemistry | ACHIRAL |
Molecular Formula | C27H28N4O5S |
Molecular Weight | 520.6 |
Optical Activity | NONE |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
CC(C)OC(=O)COC1=CC(CN(CC2=CC=C(C=C2)N3C=CC=N3)S(=O)(=O)C4=CN=CC=C4)=CC=C1
InChI
InChIKey=NVPXUFQLKWKBHK-UHFFFAOYSA-N
InChI=1S/C27H28N4O5S/c1-21(2)36-27(32)20-35-25-7-3-6-23(16-25)19-30(37(33,34)26-8-4-13-28-17-26)18-22-9-11-24(12-10-22)31-15-5-14-29-31/h3-17,21H,18-20H2,1-2H3
Molecular Formula | C27H28N4O5S |
Molecular Weight | 520.6 |
Charge | 0 |
Count |
|
Stereochemistry | ACHIRAL |
Additional Stereochemistry | No |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Optical Activity | NONE |
Taprenepag isopropyl (also known as PF-04217329) a prodrug of CP-544326 (active acid metabolite), a potent and selective EP(2) receptor agonist. Taprenepag isopropyl was studied in a clinical trials phase II involving patients with primary open angle glaucoma. According to Pfizer’s pipelines in May 2011, the study was discontinued.
Originator
Approval Year
Sample Use Guides
In Vivo Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/21851167
Stage I: 3 cohorts (total n = 67) received 1 drop of taprenepag isopropyl unit dose formulation qPM/eye for 14 days: low dose: 0.0025%, 0.005%, vehicle; middle dose: 0.01%, 0.015%, vehicle; high dose: 0.02%, 0.03%, vehicle. Stage II: 7 groups (total n = 250) received 1 drop of taprenepag isopropyl multidose formulation qPM/eye for 28 days: 0.005%, 0.01%, 0.015% monotherapy; each in unfixed combination with latanoprost 0.005%, or latanoprost monotherapy.
Route of Administration:
Other
Substance Class |
Chemical
Created
by
admin
on
Edited
Fri Dec 15 19:41:47 GMT 2023
by
admin
on
Fri Dec 15 19:41:47 GMT 2023
|
Record UNII |
81LDP7XIYG
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Name | Type | Language | ||
---|---|---|---|---|
|
Official Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
NCI_THESAURUS |
C78568
Created by
admin on Fri Dec 15 19:41:47 GMT 2023 , Edited by admin on Fri Dec 15 19:41:47 GMT 2023
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
100000178169
Created by
admin on Fri Dec 15 19:41:47 GMT 2023 , Edited by admin on Fri Dec 15 19:41:47 GMT 2023
|
PRIMARY | |||
|
C152513
Created by
admin on Fri Dec 15 19:41:47 GMT 2023 , Edited by admin on Fri Dec 15 19:41:47 GMT 2023
|
PRIMARY | |||
|
DTXSID40143384
Created by
admin on Fri Dec 15 19:41:47 GMT 2023 , Edited by admin on Fri Dec 15 19:41:47 GMT 2023
|
PRIMARY | |||
|
81LDP7XIYG
Created by
admin on Fri Dec 15 19:41:47 GMT 2023 , Edited by admin on Fri Dec 15 19:41:47 GMT 2023
|
PRIMARY | |||
|
1005549-94-9
Created by
admin on Fri Dec 15 19:41:47 GMT 2023 , Edited by admin on Fri Dec 15 19:41:47 GMT 2023
|
PRIMARY | |||
|
SUB193736
Created by
admin on Fri Dec 15 19:41:47 GMT 2023 , Edited by admin on Fri Dec 15 19:41:47 GMT 2023
|
PRIMARY | |||
|
CHEMBL2105692
Created by
admin on Fri Dec 15 19:41:47 GMT 2023 , Edited by admin on Fri Dec 15 19:41:47 GMT 2023
|
PRIMARY | |||
|
WW-137
Created by
admin on Fri Dec 15 19:41:47 GMT 2023 , Edited by admin on Fri Dec 15 19:41:47 GMT 2023
|
PRIMARY | |||
|
23729077
Created by
admin on Fri Dec 15 19:41:47 GMT 2023 , Edited by admin on Fri Dec 15 19:41:47 GMT 2023
|
PRIMARY |
Related Record | Type | Details | ||
---|---|---|---|---|
|
METABOLITE ACTIVE -> PRODRUG |
|
Related Record | Type | Details | ||
---|---|---|---|---|
|
ACTIVE MOIETY |